SMi's 20th Annual Pain Therapeutics Conference

Memo

Remote Access Only - Announcement: Due to ongoing concerns over COVID-19 we have now made this conference a virtual event. All speakers, attendees and sponsors will be able to access the full conference and its materials and will be able to log on remotely via the internet. Please contact a member of the SMi Team for more information This email address is being protected from spambots. You need JavaScript enabled to view it. The 20th Annual Conference will overview the current state of pain treatment starting with research essentials including choosing the right preclinical models to overviewing clinical success up to date, highlighting cutting-edge research and evaluating the potential of drug candidates in the pipelines of leading pharmaceuticals. This year we are introducing the Pain Research Essentials theme to closely observe analgesics drug development from a preclinical point of view. Within this theme talks will address the latest biomarker discoveries, bridging the translational gap, differences of pain pathology across sexes and consequently, the need for distinct gender animal models. This will be topped with a panel discussion around novel drug targets in neuropathic pain treatment. Presentations on clinical stage research will highlight current struggles of opioid-based treatments and discuss results of treatments with non-opioid targets; such as the recently researched cannabinoid receptor 2, nociception/orphanin FQ peptide (NOP) receptor, ENKephalinase and NGF receptors. Furthermore, neuro-immune interactions and their role in pain pathology will be discussed as an anticipated approach for providing more effective therapy for chronic pain. Additionally, the therapeutic efficacy of neurotoxins will be addressed exploring novel botulinum-based constructs. URLs:Tickets:  https://go.evvnt.com/585120-2?pid=5569 Brochure: https://go.evvnt.com/585120-5?pid=5569  Date and Time: On Monday May 11, 2020 at 8:30 am ends Tuesday May 12, 2020 at 5:00 pm Prices:REMOTE ACCESS ONLY: GBP 999.00,Distribution of Literature at Confernece: GBP 999.00,Conference Presentations (hard copy): GBP 499.00,Conference Presentations (online): GBP 300.00 Speakers: CO-CHAIR: Kerrie Brady, Chief Business Officer, Centrexion Therapeutics, CO-CHAIR: Michael Scherz, Founder and CEO, Metys Pharma